Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~For all subjects:~* Subjects who the investigator believes that they and/or their Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol.~* Written informed consent obtained from the subject/from the LAR(s).~For unprimed subjects:~* A male or female child aged 18 to 47 months at the time of the first vaccination.~* Children who did not have influenza vaccine in a previous season.~For primed subjects from study NCT00764790:~• Children who received Fluarix™ in the 111751 study NCT00764790.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* History of hypersensitivity to any vaccine.~* History of allergy or reactions likely to be exacerbated by any component of the vaccine.~* Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before and ending 28 days after each dose of vaccine(s).~* Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history and physical examination.~* Acute disease at the time of enrolment.~* History of Guillain Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.~* Receipt of another seasonal influenza vaccine outside of this study, during current (2009-2010) flu season.~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccination Inhaled and topical steroids are allowed.~* Administration of immunoglobulins and/or blood products within the 3 month preceding the first dose of study vaccine or planned administration during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 47 Months
- Healthy Volunteers: t

Study Arms:
- GSK2321138A Group (Type: EXPERIMENTAL): Subjects aged between 18 and 47 months received the GSK2321138A. Primed subjects (subjects who had received a 2-dose priming immunization with Fluarix™ vaccine in study NCT00764790 - or the GSK2321138A-Primed Group) received 1 dose of GSK2321138A vaccine at Day 0. Unprimed subject (subjects who had not received any 2-dose priming influenza immunization in any previous year - or the the GSK2321138A-Unprimed Group) received 2 doses of GSK2321138A vaccine at Days 0 and 28. The GSK2321138A vaccine was administered intramuscularly in the deltoid of the right arm.
- Fluarix Group (Type: ACTIVE_COMPARATOR): Subjects aged between 18 and 47 months received the Fluarix™ vaccine. Primed subjects (subjects who had received a 2-dose priming immunization with Fluarix™ vaccine in study NCT00764790 - or the Fluarix-Primed Group) received 1 dose of Fluarix™ vaccine at Day 0. Unprimed subject (subjects who had not received any 2-dose priming influenza immunization in any previous year - or the the Fluarix-Unprimed Group) received 2 doses of Fluarix™ vaccine at Days 0 and 28. The Fluarix™ vaccine was administered intramuscularly in the deltoid of the right arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).